姓名：陈建军
职称：教授（三级岗），博士生导师
联系邮箱：jchen21@smu.edu.cn
联系电话：020-62789423
学习经历：
2006.8-2011.1 美国田纳西大学，药物化学，博士
2004.5-2006.5 韩国江原国立大学，药物化学，硕士
1998.9-2003.7 沈阳药科大学 ，药学（英语），本科
工作经历：
2017.8- 南方医科大学药学院，教授
2015.8-2017.8 美国芝加哥州立大学药学院，助理/副教授 (Assistant/Associate Professor, tenure track)
2014.1-2015.8 美国南方药学院，助理教授 (Assistant Professor)
2011.1-2013.12 美国田纳西大学， Research Specialist
2006.8-2011.1 美国田纳西大学，Research Assistant
研究方向： 肿瘤/炎症免疫小分子调节剂的发现
主要学术任职：
1. J Med Chem 顾问编委 (Editorial Advisory Board Member)
2. 药学学报（APSB）中英文，青年编委
3. 广东省药学会-药物化学专业委员会副主任委员
4. 广东省药理学会第二届药物筛选与评价专业委员会常务委员
主要获奖情况：
1. 立德树人-感动南医好导师, 南方医科大学，2022
2. 青年海外高层次人才项目，中组部， 2017
3. “New Investigator Award”，美国药学院联合会/AACP， 2016
主要科研课题：
1. 国家自然科学基金面上项目。2024-2027，主持。
2. 国家自然科学基金面上项目。2022-2025，主持。
3. 广东省科技厅国际合作项目：靶向维生素D受体(VDR)的激动剂作为抗癌药物的研究与开发。2019-2021，主持。
4. 广东省高水平大学建设/ 南方医科大学高层次人才引进科研启动项目。2017-2020，主持。
5. 中组部青年海外高层次人才项目。2017-2022， 主持。
6. 美国国立卫生研究院/NIH/NIGMS, SC3, 1SC3GM122599。2016-2018。主持 (PI)。
7. 美国药学院联合会/AACP, New Investigator Award。2016-2017。主持(PI)。
近5年论文发表：
1. Binbin Cheng, Yaru Shi, Chuxiao Shao, Shuanghu Wang, Zhenhong Su, Jin Liu, Yingxing Zhou, Xiaoting Fei, Wei Pan*, Jianjun Chen*, Yiyu Lu*, Jian Xiao*. Discovery of Novel Hetero-tricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer Immunotherapy. J Med Chem 2024 accepted (IF=8.039, 小类1区)
2. Xin Ma, Shengpan Wu, Bao-Jun Wang, Hongzhao Li, Hanfeng Wang, Songliang Du, Xing Huang, Yang Fan, Yu Gao, Liangyou Gu, Qingbo Huang, Jianjun Chen, Xu Zhang*, and Yan Huang*. Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma. Oncogene 2024 accepted.
3. Junli Huang#, Zeli Ma#, Xiaopeng Peng#, Zichao Yang, Yuhao Wu, Guanghong Zhong, Tianfeng Ouyang, Zhen Chen, Yao Liu, Qirui Wang, Jianjun Chen*, Ting Chen*, Zhenhua Zeng*. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases. J Med Chem 2024 Feb 22;67(4):2438-2465. doi: 10.1021/acs.jmedchem.3c01414. (IF=8.039, 小类1区).
4. Xiaopeng Peng#, Zhihao Hu#, Limei Zeng, Meizhu Zhang, Congcong Xu, Benyan Lu, Chengpeng Tao, Weiming Chen, Wen Hou, Kui Cheng*, Huichang Bi*, Wanyi Pan*, Jianjun Chen*. Overview of Epigenetic Degraders Based on PROTAC, Molecular Glue, and Hydrophobic Tagging Technologies. Acta Pharmaceutica Sinica B, 2024, Feb, 14(2), 533-578, doi.org/10.1016/j.apsb.2023.09.003 (IF=14.903, 小类1区)
5. Binbin Cheng#, Wei Pan#, Yao Xiao#, Zongbao Ding#, Yingxing Zhou, Xiaoting Fei, Jin Liu, Zhenhong Su*, Xiaopeng Peng*, Jianjun Chen*, HDAC-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem, 2024 Feb 5:265:116129. (IF=7.088, 小类1区)
6. 王志杰，廖晓彤，郭霞*，陈建军**. 靶向PD-1/PD-L1的新策略：降解剂、双功能分子及共价抑制剂。《中国药科大学学报》，2023年12月25日接收（IF=1.138）
7. Deping Li#, Xiaopeng Peng#, Zhihao Hu#, Shuqing Li, Jianjun Chen*, Wanyi Pan*, Small Molecules Targeting Selected Histone Methyltransferases (HMTs) for Cancer Treatment: Current Progress and Novel Strategies. Eur J Med Chem., 2023 Nov 25;264:115982. doi.org/10.1016/j.ejmech.2023.115982 (IF=7.088, 小类1区)
8. Zichao Yang#, Yangcheng Ai#, Guowu Wu, Fengqiu Guo, Zilong Yang, Beijun Cheng, Lishun Zhang, Mingxia Li, Jianjun Chen*, Jiajie Zhang*, Tingting Zhang*. Discovery of Conformationally Constrained C-Abl Inhibitors with Potential Neuroprotective Effects against Parkinson’s Disease. Bioorganic & Medicinal Chemistry 2023 Dec 15;96:117532. doi.org/10.1016/j.bmc.2023.117532. (IF=3.641, 小类2区)
9. Binbin Wu, Chenglong Xu, Jianjun Chen*, Guangying Chen*. Aspergilins A–B, Including a Unique Orsellinic Acid–Ribose–Pyridazinone-N-Oxide Hybrid, from the Mangrove Endophytic Fungus Aspergillus sp. A1E3. Marine Drugs, 2023 Nov 19;21(11):598. doi: 10.3390/md21110598. (IF=6.085, 小类2区)
10. Jin Liu#*, Yao Cheng#, Lin Yuan#, Ting Liu#, Yong Ruan, Yichang Ren, Ling Li, Sheng Jiang*, Yibei Xiao*, Jianjun Chen*. Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (non-arylmethylamine)-based Small Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic Agents. J Med Chem, 2023 Sep 28;66(18):13172-13188. doi: 10.1021/acs.jmedchem.3c01141. (IF=8.039, 小类1区).
11. Xiaona Chen, Yi Hao, Yong Liu, Sheng Zhong, Yuehua You, Keyi Ao, Tuotuo Chong, Xiaomin Luo, Minuo Yin, Ming Ye, Hui He, Anwei Lu, Jianjun Chen, Xin Li, Jian Zhang, Xia Guo. NAT10/ac4C/FOXP1 promotes malignant progression and facilitates immunosuppression by reprogramming glycolytic metabolism in cervical cancer. Advanced Science, 2023 Nov;10(32):e2302705. http://doi.org/10.1002/advs.202302705. (IF=17.52, 1区)
12. Junli Huang#, Zeli Ma#, Zichao Yang, Zengzhu He, Jingna Bao, Xiaopeng Peng, Yao Liu, Ting Chen*, Shumin Cai*, Jianjun Chen*, Zhenhua Zeng*. Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation. Eur J Med Chem., 2023 Nov 5;259:115664. 115664. DOI: doi.org/10.1016/j.ejmech.2023.115664 (IF=7.088, 小类1区)
13. Zichao Yang#, Ziqing Liu#, Chenglong Xu, Jianwei Xu, Ting Liu, Haiqi He, Ling Li, Yichang Ren, Jianjun Chen*. Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy. Bioorganic Chemistry, 2023 July, 139:106740, 106740. DOI: doi.org/10.1016/j.bioorg.2023.106740 (IF=5.307, 小类1区).
14. Zongbao Ding, Shuanghu Wang, Yaru Shi, Xiaoting Fei, Binbin Cheng*, Yiyu Lu*, Jianjun Chen*. Discovery of Novel D(+)-Biotin-conjugated Resorcinol Dibenzyl Ether-based PD-L1 Inhibitors for Targeted Cancer Immunotherapy. J Med Chem, 2023 Aug 10;66(15):10364-10380. DOI: 10.1021/acs.jmedchem.3c00479 (IF=8.039, 小类1区).
15. Xiaopeng Peng#, Ziwen Yu#, Surineni Goverdhan#, Bulian Deng#, Meizhu Zhang, Chuan Li, Zhiqiang Sun, Wanyi Pan, Yao Liub, Shenglan Liu*, Bin Yu*, Jianjun Chen*. Discovery of Novel Benzohydroxamate-based Histone Deacetylase 6 (HDAC6) Inhibitors with the Ability to Potentiate Anti-PD-L1 Immunotherapy in Melanoma. J Enzyme Inhib Med Chem, 2023 Dec;38(1):2201408. doi: 10.1080/14756366.2023.2201408. (IF=5.756, 2区).
16. Yichang Ren#, Yuxi Wang#, Jin Liu#, Ting Liu, Lin Yuan, Chengyong Wu, Zichao Yang, Jianjun Chen*. X-ray Crystal Structure Guided Discovery of Novel Indole Analogs as Colchicine Binding Site Tubulin Inhibitors with Immune Potentiating and Antitumor Effects against Melanoma. J Med Chem, 2023 May 25;66(10):6697-6714. doi: 10.1021/acs.jmedchem.3c00011. (IF=8.039, 小类1区).
17. Binbin Cheng#, Wei Wang#, Ting Liu, Hao Cao, Wei Pan, Yao Xiao, Shuwen Liu*, Jianjun Chen*. Bifunctional Small Molecules Targeting PD-L1/CXCL12 as Dual Immunotherapy for Cancer Treatment. Signal Transduct Target Ther. (STTT)，2023 Mar 1;8(1):91. doi: 10.1038/s41392-022-01292-5. (IF=38.104, 1区).
18. Xiaopeng Peng#, Yichang Ren#, Wanyi Pan, Jin Liu, Jianjun Chen*. Discovery of Novel Acridane-based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects. J Med Chem, 2023 Jan 12, 66(1):627-640. doi: 10.1021/acs.jmedchem.2c01566 (IF=8.039, 小类1区).
19. Bulian Deng#, Zhiqiang Sun#, Yuxi, Wang#, Ruiyao Mai, Zichao Yang, Yichang Ren, Jin Liu, Junli Huang, Zeli Ma, Ting Chen, Canjun Zeng*, Jianjun Chen*. Design, Synthesis, and Bioevaluation of Imidazo [1,2-a] Pyrazine Derivatives as Tubulin Polymerization Inhibitors with Potent Anticancer Activities. Bioorganic & Medicinal Chemistry, 2022 Dec 15;76:117098. (IF=3.641, 小类2区)
20. Yinrong Wu#, Zichao Yang#, Kui Cheng*, Huichang Bi*, Jianjun Chen*. Small molecule-based immunomodulators for cancer therapy. Acta Pharmaceutica Sinica B, 2022 Dec;12(12):4287-4308 (IF=14.903, 小类1区)
21. Xiaopeng Peng#, Wanyi Pan#, Feng Jiang, Weiming Chen, Zetao Qi, Weijie Peng*, Jianjun Chen*. Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy. Pharmacol Res, 2022 Dec, 186, 106529. (IF=10.334, 小类1区)
22. Zean Zhao#, Jin Liu#, Lin Yuan#, Zichao Yang#, Peihua Kuang, Hui Liao, Jian Luo, Huancun Feng, Fengxin Zheng, Yongjun Chen, Ting Wu, Jiayin Guo, Ying Cao, Yang Yang, Cuiting Lin, Qun Zhang*, Jianjun Chen*, Jianxin Pang*. Discovery of Novel Benzbromarone Analogs with Improved Pharmacokinetics and Benign Toxicity Profiles as Antihyperuricemic Agents. Eur J Med Chem., 2022 Aug, 114682 (IF=7.088, 小类1区)
23. Ling Li#, Huiting Zhao#, Xiaopeng Peng#, Jin Liu, Ruiyao Mai, Jingxuan Chen, Lin Lin, Ting Chen, Jun Yan*, Jiaolong Shi*, Jianjun Chen*. Discovery of Novel Quinazoline-based KRAS G12C Inhibitors as Potential Anticancer Agents. Bioorganic & Medicinal Chemistry, 2022, 116962. (IF=3.641, 小类2区)
24. Zhiqiang Sun#, Bulian Deng#, Zichao Yang, Ruiyao Mai, Junli Huang, Zeli Ma, Ting Chen, Jianjun Chen*. Discovery of Pomalidomide-based PROTACs for Selective Degradation of Histone Deacetylase 8. Eur J Med Chem., 2022 Sep 5;239:114544. doi: 10.1016/j.ejmech.2022.114544. (IF=7.088, 小类1区)
25. Zongbao Ding, Wei Pan, Yao Xiao, Binbin Cheng*, Gang Huang*, Jianjun Chen*. Discovery of Novel 7,8-dihydropteridine-6(5H)-one-Based DNA-PK Inhibitors as Potential Anticancer Agents via Scaffold Hopping Strategy. Eur J Med Chem., 2022, July 5; 237, 114401. doi.org/10.1016/j.ejmech.2022.114401 (IF=7.088, 小类1区)
26. Jin Liu, Lin Yuan, Yong Ruan, Bulian Deng, Zicao Yang, Yichang Ren, Ling Li, Ting Liu, Huiting Zhao, Ruiyao Mai, Jianjun Chen*. Novel CRBN-recruiting PROTACs as Degraders of STING With In Vivo Anti-inflammatory Efficacy. J Med Chem, 2022 May 12; 65(9):6593-6611, doi.org/10.1021/acs.jmedchem. 1c01948 (IF=8.039, 小类1区).
27. Ruiyao Mai, Bulian Deng, Huiting Zhao, Ling Li, Yuyu Fang, Siming Li, Xin Deng*, Jianjun Chen*. Design, Synthesis and Bioevaluation of Novel Enzyme Triggerable Cell Penetrating Peptide (ETCPP)-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy. J Med Chem, 2022 Apr 14;65(7):5850-5865. doi: 10.1021/acs.jmedchem.2c00287. (IF=8.039, 小类1区).
28. Huiting Zhao#, Ling Li#, Jin Liu, Ruiyao Mai, Jingxuan Chen, Jianjun Chen*. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity. Bioorganic Chemistry, 2022 April, 121, 105652. doi.org/10.1016/j.bioorg.2022.105652 [IF=5.307, 小类1区(2021升级版)].
29. Yuanxing Zhi#, Jin Liu#, Peihua Kuang, Xin Zhang, Ziwei Xu, Yanshan Chen, Xiulin Lin, Xiaoyan Wu, Pingzheng Zhou*, Jianjun Chen*. Novel DCPIB analogs as dual inhibitors of VRAC/TREK1 channels reduced cGAS-STING mediated interferon responses. Biochem Pharmacol. 2022 Mar 9;114988. doi: 10.1016/j.bcp.2022.114988. (IF=6.100, 小类2区)
30. Ling Li#, Jin Liu#, Zichao Yang, Huiting Zhao, Bulian Deng, Yichang Ren, Ruiyao Mai, Junli Huang, Jianjun Chen*. Discovery of Thieno[2,3-d]pyrimidine-Based KRAS G12D Inhibitors as Potential Anticancer Agents via Combinatorial Virtual Screening. Eur J Med Chem., 2022 Feb, 114243. (IF=7.088, 小类1区)
31. Xiaopeng Peng#, Ling Li#, Jingxuan Chen#, Yichang Ren, Jin Liu, Ziwen Yu, Hao Cao, Jianjun Chen*. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma. J Med Chem, 2022 Feb 10;65(3):2434-2457. doi.org/10.1021/acs.jmedchem.1c01863 (IF=8.039, 小类1区).
32. Ling Li#, Sijie Yuan#, Lin Lin, Fang Yang, Ting Liu, Chenglong Xu, Huiting Zhao, Jingxuan Chen, Peihua Kuang, Ting Chen*, Wenzhen Liao*, Jianjun Chen*. Discovery of Novel 2-Aryl-4-Bis-amide Imidazoles (ABAI) As Anti-inflammatory Agents for the Treatment of Inflammatory Bowel Diseases (IBD). Bioorganic Chemistry, 2022, 120, 105619. doi.org/10.1016/j.bioorg.2022.105619 [IF=5.307, 小类1区(2021升级版)].
33. Binbin Cheng#, Wei Pan#, Yi Xing#, Yao Xiao#, Jianjun Chen*, Zheng Xu*. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. Eur J Med Chem, 2022, February 15, 230, 114109. (IF=7.088, 小类1区)
34. Zean Zhao#, Jin Liu#, Peihua Kuang#, Jian Luo, Goverdhan Surineni, Xiaolin Cen, Ting Wu, Ying Cao, Pingzheng Zhou, Jianxin Pang*, Qun Zhang*, Jianjun Chen*. Discovery of Novel Verinurad Analogs as Dual Inhibitors of URAT1 and GLUT9 with Improved Druggability for the Treatment of Hyperuricemia. Eur J Med Chem., 2022, Feb 3, 229, 114092. (IF=7.088, 小类1区)
35. Yuxin Zhuang#, Guang Yang#, Shaoyu Wu, Jianjun Chen, Jiayin Guo, Dongling Quan, Tingting Zhang, Zichao Yang, Shaobin Tan, Yuheng Ji*, Zhipeng Chen*, Lin Lv*. 5-Arylalkynyl-2-Benzoyl Thiophene: A Novel Microtubule Inhibitor Exhibits Antitumor Activity without Neurological Toxicity. American Journal of Cancer Research, 2022 Jan 15;12(1):229-246. (IF=6.166, 小类2区).
36. Ling Li, Yinrong Wu, Zichao Yang, Chenglong Xu, Huiting Zhao, Jin Liu, Jingxuan Chen, Jianjun Chen*. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity. Bioorganic Chemistry, 2021 Oct 22;117:105447. doi: 10.1016/j.bioorg.2021.105447. [IF=5.307, 小类1区(2020升级版)；小类2区(2020基础版)]
37. Yichang Ren, Yong Ruan, Binbin Cheng, Ling Li, Jin Liu, Yuyu Fang, Jianjun Chen*. Design, Synthesis and Biological Evaluation of Novel Acridine and Quinoline Derivatives as Tubulin Polymerization Inhibitors with Anticancer Activities. Bioorganic & Medicinal Chemistry, 2021 Aug 23;46:116376. doi: 10.1016/j.bmc.2021.116376. [IF=3.641, 小类2区(2020升级版)；小类3区(2020基础版)]
38. Xin Deng#, Ruiyao Mai#, Chenyu Zhang, Jiaqi Liu, Yichang Ren, Gang Li, Jianjun Chen*. Synthesis and pharmacological evaluation of a novel synthetic peptide CWHTH based on the Styela clava-derived natural peptide LWHTH with improved antioxidant, hepatoprotective and angiotensin converting enzyme inhibitory activities. International Journal of Pharmaceutics. 2021 Aug 10;605:120852. doi: 10.1016/j.ijpharm.2021.120852. [IF=5.875, 小类1区(2020升级版)；小类2区(2020基础版)].
39. Jingxuan Chen#, Ling Li#, Jin Liu, Sijie Yuan, Wenzhen Liao, Andrzej T. Slominski, Wei Li, Michał A Żmijewski, Jianjun Chen*. Discovery of Novel 3-Hydroxyandrosta-5,7-Diene-17-Carboxylic Acid Derivatives as Anti-Inflammatory Bowel Diseases (IBD) Agents. Eur J Med Chem, 2021 Aug 5, 220, 113468. DOI: 10.1016/j.ejmech.2021.113468. (IF=7.088, 小类1区)
40. Hao Zhong, Pei-Ying Huang, Ping Yan, Pei-Ling Chen, Qun-Yin Shi, Ze-An Zhao , Jing-Xuan Chen, Xian Shu, Ping Wang, Bin Yang, Zheng-Zheng Zhou, Jian-Jun Chen, Jian-Xin Pang, Ying-Feng Tu, Li-Han Liu, Xian-Zheng Zhang. Versatile Nanodrugs Containing Glutathione and Heme Oxygenase 1 Inhibitors Enable Suppression of Antioxidant Defense System in a Two-Pronged Manner for Enhanced Photodynamic Therapy. Adv Healthc Mater. 2021 Jun 30;e2100770. doi: 10.1002/adhm.202100770. (IF=11.092, 小类1区).
41. Yupeng Wang, Zhijian Luo, Dongfang Zhou, Xuefeng Wang, Jianjun Chen, Shipeng Gong, Zhiqiang Yu. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer. Biomater Sci. Biomater Sci. 2021 Jun 4;9(11):4110-4119. doi: 10.1039/d1bm00087j. (IF=7.590, 1区)
42. Xin Liu, Yuanyuan Yang, Mingjian Ling, Rui Sun, Meiyan Zhu, Jianjun Chen, Meng Yu, Zhenwei Peng*, Zhiqiang Yu*, Xiqiang Liu*. Near‐Infrared II Light‐Triggered Robust Carbon Radical Generation for Combined Photothermal and Thermodynamic Therapy of Hypoxic Tumors. Advanced Functional Materials. DOI: 10.1002/adfm.202101709. (IF=18.808, 1区)
43. Xiaopeng Peng#, Jingxuan Chen#, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, Jianjun Chen*. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin / Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. J Med Chem., 2021 Jun 24;64(12):8447-8473. doi: 10.1021/acs.jmedchem.1c00413. (IF=8.039, 小类1区).
44. Hao Cao, Binbin Cheng, Ting Liu, Jianjun Chen*. Synthesis and Pharmacological Evaluation of Novel Resorcinol Biphenyl Ether Analogs as Small Molecule Inhibitors of PD-1/PD-L1 with Benign Toxicity Profiles for Cancer Treatment. Biochemical Pharmacology, 2021 Jun;188:114522. doi: 10.1016/j.bcp.2021.114522. (IF=6.100, 小类1区)
45. Ling Li, Huiting Zhao, Hui Liao, Jingxuan Chen, Jin Liu, Jianjun Chen*. Discovery of Novel Quinazoline-based Covalent Inhibitors of KRAS G12C with Various Cysteine-targeting Warheads as Potential Anticancer Agents. Bioorganic Chemistry, 2021 May;110:104825. doi: 10.1016/j.bioorg.2021.104825. [IF=5.275, 小类1区(2020升级版)；小类2区(2019基础版)].
46. Buduma Komuraiah#, Yichang Ren#, Mingming Xue, Binbin Cheng, Jin Liu, Yao Liu*, Jianjun Chen*. Design, Synthesis and Biological Evaluation of Benz-Fused Five-Membered Heterocyclic Compounds as Tubulin Polymerization Inhibitors with Anticancer Activities. Chemical Biology & Drug Design, 2021 May;97(5):1109-1116. doi: 10.1111/cbdd.13832. (IF=2.817, 小类3区).
47. Yichang Ren#, Yuxi Wang#, Gang Li#, Zherong Zhang, Lingling Ma, Binbin Cheng, Jianjun Chen*. Discovery of Novel Benzimidazole and Indazole Analogs as Tubulin Polymerization Inhibitors With Potent Anticancer Activities. J Med Chem., 2021 Apr 22;64(8):4498-4515. doi: 10.1021/acs.jmedchem.0c01837. (IF=8.039, 小类1区)
48. Xuchao Yang#, Binbin Cheng#, Yao Xiao#, Mingming Xue, Ting Liu, Hao Cao, Jianjun Chen*. Discovery of Novel CA-4 Analogs as Dual Inhibitors of Tubulin Polymerization and PD-1/PD-L1 Interaction for Cancer Treatment. Eur J Med Chem., 2021 Mar 5; 213:113058. doi: 10.1016/j.ejmech.2020.113058. (IF=7.088, 小类1区)
49. Xin Deng, Ruiyao Mai, Chenyu Zhang, Dianbao Yu, Yichang Ren, Gang Li, Binbin Cheng, Ling Li, Zhiqiang Yu, Jianjun Chen*, Discovery of Novel Cell-penetrating and Tumor-targeting Peptide-Drug Conjugate (PDC) for Programmable Delivery of Paclitaxel and Cancer Treatment. Eur J Med Chem., 2021 Mar 5; 213:113050. doi: 10.1016/j.ejmech.2020.113050. (IF=7.088, 小类1区)
50. Gang Li, Wenqing Qi, Xiaoxun Li, Jinwu Zhao, Meihua Luo, Jianjun Chen*. Recent Advances in c-Jun N-terminal Kinase (JNK) Inhibitors. Current Medicinal Chemistry, 2021, 28(3):607-627. (IF=4.530, 小类3区).
51. Binbin Cheng#, Yao Xiao#, Mingming Xue#, Hao Cao, Jianjun Chen*, Recent advances in the development of PD-L1 modulators: degraders, downregulators, and covalent inhibitors. J Med Chem., 2020 Dec 24; 63(24):15389-15398. DOI: 10.1021/acs.jmedchem.0c01362. (IF=8.039, 小类1区)
52. Binbin Cheng, Wei Wang, Xiaoge Niu, Yichang Ren, Ting Liu, Hao Cao, Shuanghu Wang, Yingfeng Tu, Jingxuan Chen, Shuwen Liu, Xuchao Yang, Jianjun Chen*. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. J Med Chem., 2020 Dec 24;63(24):15946-15959. DOI: 10.1021/acs.jmedchem.0c01684. (IF=8.039, 小类1区)
53. Xiaopeng Peng#, Zhiqiang Sun#, Peihua Kuang#, and Jianjun Chen*. Recent Progress on HDAC Inhibitors with Dual Targeting Capabilities for Cancer Treatment. Eur J Med Chem., 2020 Dec 15;208:112831. (IF=7.088, 小类1区).
54. Jingxuan Chen, Ziyu Tang, Andrzej T. Slominski, Wei Li, Michał A Żmijewski, Yao Liu*, Jianjun Chen*. Vitamin D and its analogs as anticancer and anti-inflammatory agents. Eur J Med Chem., 2020 Dec 1;207:112738. (IF=7.088, 小类1区).
55. Gang Li, Yuxi Wang, Ling Li, Yichang Ren, Xin Deng, Jin Liu, Wei Wang, Meihua Luo, Shuwen Liu, Jianjun Chen*. Design, Synthesis, and Bioevaluation of Pyrazolo[1,5-a]Pyrimidine Derivatives as Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site with Potent Anticancer Activities. Eur J Med Chem., 2020 Sep 15; 202:112519. (IF=7.088, 小类1区).
56. Binbin Cheng, Yichang Ren, Wei Wang, Shuanghu Wang, Yingfeng Tu, Shuwen Liu, Jin Wang, Deying Yang, Guochao Liao, Jianjun Chen*. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction As Potential Anticancer Agents. J Med Chem., 2020 Aug 13; 63(15):8338-8358. (IF=8.039, 小类1区)
57. Xiaopeng Peng#, Zhiqiang Sun#, Peihua Kuang, Ling Li, Jingxuan Chen, Jianjun Chen*. Copper Catalyzed Selective Arylation of Nitriles with Cyclic Diaryl Iodonium Salts: A Direct Access to Structurally Diversified Diarylmethane Amides with Potential Neuroprotective and Anticancer Activities. Organic Letters, 2020 Aug 7; 22(15):5789-5795. (IF=6.005, 大小类均为1区)
58. Binbin Cheng, Yichang Ren, Hao Cao, Jianjun Chen*. Discovery of Novel Resorcinol Diphenyl Ether-based PROTAC-like molecules as Dual Inhibitors and Degraders of PD-L1. Eur J Med Chem., 2020 Aug 1;199:112377. (IF=7.088, 小类1区).
59. Xiaopeng Peng, Ling Li, Yichang Ren, Huanxin Xue, Jin Liu, Shjijun Wen, Jianjun Chen*. Synthesis of N‐Carbonyl Acridanes as Highly Potent Inhibitors of Tubulin Polymerization via One‐Pot Copper‐Catalyzed Dual Arylation of Nitriles with Cyclic Diphenyl Iodoniums. Advanced Synthesis and Catalysis, 2020, May 12, 362 (10), 2030-2038. (IF=5.837, 小类1区).
60. Youmei Bao, Shenqi Zhang, Zeming Chen, Ann Chen, Junning Ma, Gang Deng, Weiguo Xu, Jiangbing Zhou, Zhi-Qiang Yu, Guangyu Yao*, Jianjun Chen*. Synergistic chemotherapy for breast cancer and breast cancer brain metastases via paclitaxel-loaded oleanolic acid nanoparticles. Molecular Pharmaceutics, 2020 Apr 6;17(4):1343-1351. (IF=5.364, 小类1区(2020升级版)；小类2区(2019基础版).
61. Wen Ma, Sui-Nan Sha, Pei-Ling Chen, Meng Yu, Jian-Jun Chen, Chao-Bo Huang, Bin Yu, Yun Liu, Li-Han Liu, Zhi-Qiang Yu. A Cell Membrane-Targeting Self-Delivery Chimeric Peptide for Enhanced Photodynamic Therapy and In Situ Therapeutic Feedback. Adv Healthc Mater. 2020 Jan;9(1):e1901100. (IF=9.933, 小类1区).
62. Ling Li#, Dongling Quan#, Jingxuan Chen, Jiahao Ding, Jinwu Zhao, Lin Lv*, Jianjun Chen*. Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents. Eur J Med Chem., 2019, Dec 15, 184:111732. (IF=7.088, 小类1区).
63. Hao Cao#, Ling Li#, Deying Yang, Liming Zeng, Yewei Xie, Bin Yu*, Guochao Liao*, Jianjun Chen*, Recent Progress in Histone Methyltransferase (G9a) Inhibitors as Anticancer Agents. Eur J Med Chem., 2019 Oct 1, 179:537-546. (IF=7.088, 小类1区).
64. Jingxuan Chen, Sibo Jiang, Jin Wang, Jwala Renukuntla, Suman Sirimulla and Jianjun Chen*. A Comprehensive Review of Cytochrome P450 2E1 for Xenobiotic Metabolism. Drug Metabolism Reviews. 2019 May, 51(2):178-195. (IF=6.984, 小类1区 (2020升级版)；小类2区(2019基础版))
65. Xiaopeng Peng, Guochao Liao, Pinghua Sun, Zhiqiang Yu, Jianjun Chen*, An overview of HDAC inhibitors and their synthetic routes. Current Topics in Medicinal Chemistry, 2019, 19(12):1005-1040. (IF=3.570, 小类3区)
66. Wu, Peng; Wang, Xuefeng; Wang, Zigui; Ma, Wen; Guo, Jinshan; Chen, Jianjun; Yu, Zhiqiang; Li, Jizhen; Zhou, Dongfang. Light-Activatable Prodrug and AIEgen Copolymer Nanoparticle for Dual-Drug Monitoring and Combination Therapy. ACS Appl Mater Interfaces. 2019 May 22,11(20):18691-18700. (IF=9.229, 大类1区)
67. Xiaoming Li, Xiaoshuang Guo, Yuan Cheng, Xiaotian Zhao, Zhiwei Fang, Yanli Luo, Shujun Xia, Yun Feng, Jianjun Chen*, Weien Yuan*. pH-responsive cross-linked low molecular weight polyethylenimine as an efficient gene vector for delivery of plasmid DNA encoding anti-VEGF-shRNA for tumor treatment. Frontiers in Oncology, 2018 Sep 25, 8:354. (IF=6.244, 小类2区)
68. Xiaoshuang Guo; Yuan Cheng; Xiaotian Zhao; Yanli Luo; Jianjun Chen*, Wei-En Yuan*. Advances in redox-responsive drug delivery systems of tumor microenvironment, Journal of Nanobiotechnology, 2018 Sep 22;16(1):74. (IF=10.435, 小类1区)
69. Binbin Cheng, Wei-En Yuan, Jing Su, Yao Liu, Jianjun Chen*, Recent Advances in Small Molecule based Cancer Immunotherapy, Eur J Med Chem., 2018 Sep 5, 157:582-598. (IF=7.088, 小类1区)
70. Sibo Jiang, Yesenia L Franco, Yan Zhou, Jianjun Chen*, Nanotechnology in Retinal Drug Delivery, International Journal of Ophthalmology, 2018 Jun 18, 11(6), 1038-1044. (IF=1.779, 小类3区)
71. Xiaoxun Li, Peter D. Livant, Jianjun Chen*, An alkene-forming cascade reaction en route to 2,2'-bi(glycerol), SynLett, 2018 June 12; 29(13): 1769-1772. (IF=2.454, 小类3区)
72. Ling Li, Sibo Jiang, Xiaoxun Li, Yao Liu, Jing Su, Jianjun Chen*, Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site, Eur J Med Chem., 2018 May 10, 151, 482-494. (IF=7.088, 小类1区)
近5年专利申请/授权：
1. 郭霞 ，陈建军，敖可翊，孙志强。一种可抑制宫颈癌增殖的化合物及其制备方法与应用。202310323589.8。申请公开号：CN116514798A，2023-08-01（申请中）
2. 陈建军，孙志强。基于邻苯二胺及酰肼类HDAC PD-L1双功能分子合成及其用途。2023104486728。2023.8.9（申请中）
3. 陈建军，杨梓超，刘子晴。一种环状小分子化合物及其制备方法与应用。专利申请号: 2023108603877， 2023年7月13日（申请中）
4. 陈建军，刘进，刘婷。一种联苯噁二唑醚类衍生物作为PD-1/PD-L1小分子抑制剂及其合成方法和用途。2023107610869， 2023年6月30日（申请中）
5. 陈建军，刘叔文，程斌斌，刘婷。一种PD-L1/CXCL12双靶点抑制剂、制备方法和用途。专利号: ZL2022109670272，授权公告号：CN 115403510 B；2023年4月25号（已授权）
6. 彭孝鹏，陈建军，一种sabizabulin的制备方法。专利申请号: 202210569610.8，2022年5月25号
7. 陈建军，彭孝鹏。一种化合物及其制备方法与应用。专利号: ZL 2022105086569，授权公告号：CN 115010658 B； 2023年6月27号（已授权）
8. 陈建军，彭孝鹏，李玲，陈镜玄。一种异羟肟酸类化合物及其用途专利。专利号：：ZL 202111642489.9；授权公告号：CN 114315754 B，2023年6月6号（已授权）
9. 陈建军，黄俊力。一种BTK抑制剂及其制备方法与应用。专利号：ZL 202111542048.1；授权公告号：CN 114292270 B，2023年5月5号（已授权）
10. 陈建军，刘进。一种富马酸酰胺类化合物或其药学上可接受的盐及其制备方法和应用。专利号：ZL 202111349746.X；授权公告号：CN 114085215 B，2023年7月25号（已授权）
11. 庞建新，陈建军，田园新，吴婷，赵泽安，邝沛华，刘进，李璐，李咏梅。一种吡啶-3胺衍生物及其制备方法和应用，专利申请号：CN202111171863.1，授权公告号：CN113979931B，2023.06.13 （已授权）
12. 陈建军，李玲，赵慧婷。一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用。专利申请号：202111230609.4，授权公告号：CN113956233B，2023.06.06 （已授权）
13. 李刚，陈建军，任益昌，姚宏亮，王华敏，关文。一种7-(3,4-二甲氧基-5-硒甲基苯基)-吡咯并[2, 3-d]嘧啶及其应用。专利申请号：ZL 202110235392.X （已授权）
14. 陈建军、邓欣、麦瑞堯、任益昌、程斌斌。一种多肽-紫杉醇偶联物及其应用。专利申请号：ZL 202010488241.0（已授权）
15. 陈建军, 李刚, 邓欣, 任益昌, 李玲. 一种7-(三甲氧基苯基)-吡咯并[2, 3-d]嘧啶及其应用. 中国专利：ZL 2019108330613.0（已授权）
16. 陈建军，程斌斌。一种泊马度胺衍生物及其用途。专利申请号：202010262495.0，2020.04.07
17. 陈建军，彭孝鹏。一种N-羰基-9，10-二氢吖啶类化合物的制备方法及其应用。专利申请号：201911098382.5; 2019.11.12（已授权）
18. 陈建军，程斌斌。一种含取代联苯的间苯二酚甲醚衍生物及其用途。。专利申请号： 201910136927.0 / CN 109761952 A; 2019.05.17
19. 陈建军，任益昌，程斌斌。一种苯并五元杂环衍生物及其应用。专利申请号：201910812479.1。2019.08.30（已授权）
20. 陈建军, 李刚, 邓欣, 任益昌, 李玲. 一种7-(三甲氧基苯基)-吡咯并[2, 3-d]嘧啶及其应用. 中国专利：2019108330613.0
